RCT: Oral Roxadustat vs. Epoetin Alfa for treating anemia in patients with chronic kidney disease on dialysis.

Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study – Journal of the American Society of Nephrology

Related:

Randomized Trials: Evaluation of New Treatment for Anemia of Chronic Kidney

RCT: Efficacy and safety of Daprodustat (oral drug) for treating anemia of chronic kidney disease in incident dialysis patients.

RCT: In patients with chronic kidney diseases and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes.

RCT: In patients with chronic kidney diseases and anemia not undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa in increasing hemoglobin levels and regarding cardiovascular outcomes.